Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study ; volume:8 ; number:4 ; day:16 ; month:6 ; year:2017 ; pages:887-898 ; date:8.2017
Diabetes therapy ; 8, Heft 4 (16.6.2017), 887-898, 8.2017
- Keyword
-
Endokrinologie
- Contributor
-
Bu, Shi
Zhang, Xuelian
Zhu, Haiqing
Shuai, Ying
Xing, Xiaoyan
Yang, Wenying
SpringerLink (Online service)
- DOI
-
10.1007/s13300-017-0284-1
- URN
-
urn:nbn:de:1111-2017102012088
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bu, Shi
- Zhang, Xuelian
- Zhu, Haiqing
- Shuai, Ying
- Xing, Xiaoyan
- Yang, Wenying
- SpringerLink (Online service)
Other Objects (12)
Switching From Pre-mixed Insulin to Regimens with Insulin Glargine in Type 2 Diabetes: A Prospective, Observational Study of Data From Adriatic Countries
Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis
Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
Switching from Premixed Insulin to Insulin Degludec/Insulin Aspart for the Management of Type 2 Diabetes Mellitus: Implications of a Real-World Study on Insulin Degludec Dosing
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
Correction to: MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
Comparison between Insulin Glargine and Insulin Detemir in Adolescents with Type 1 Diabetes during Ramadan Fasting
Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
Switching From Pre-mixed Insulin to Regimens with Insulin Glargine in Type 2 Diabetes: A Prospective, Observational Study of Data From Adriatic Countries
Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis
Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
Switching from Premixed Insulin to Insulin Degludec/Insulin Aspart for the Management of Type 2 Diabetes Mellitus: Implications of a Real-World Study on Insulin Degludec Dosing
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
Correction to: MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
Comparison between Insulin Glargine and Insulin Detemir in Adolescents with Type 1 Diabetes during Ramadan Fasting
Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
Switching From Pre-mixed Insulin to Regimens with Insulin Glargine in Type 2 Diabetes: A Prospective, Observational Study of Data From Adriatic Countries
Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis
Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
Switching from Premixed Insulin to Insulin Degludec/Insulin Aspart for the Management of Type 2 Diabetes Mellitus: Implications of a Real-World Study on Insulin Degludec Dosing
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
Correction to: MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
Comparison between Insulin Glargine and Insulin Detemir in Adolescents with Type 1 Diabetes during Ramadan Fasting
Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients